Adenosinergic Signaling Alters Natural Killer Cell Functional Responses

Andrea M. Chambers, Jiao Wang, Kyle B. Lupo, Hao Yu, Nadia A. Lanman, Sandro MatosevicFrontiers in Immunology 2018 · DOI

TL;DR

This study reveals that adenosine, a molecule often found in tumors, can suppress natural killer (NK) cell anti-tumor activity. However, the impact of adenosine is not uniform; it depends heavily on how NK cells are "primed" with specific cytokines. Notably, NK cells primed with a combination of IL-12 and IL-15 are particularly sensitive to adenosine, leading to altered immune signaling and metabolic functions, which could be a target for new cancer therapies.

What Problem Does This Paper Address?

Solid tumors create an immunosuppressive microenvironment, partly due to high levels of adenosine. This adenosine can dampen the activity of Natural Killer (NK) cells, which are crucial for innate immunity and fighting cancer. While it's known that adenosine generally inhibits NK cell function, the precise mechanisms and how this inhibition is modulated by different activation states of NK cells remain unclear. Specifically, how cytokine priming, a common strategy in immunotherapy, influences NK cell responses to adenosine is not well understood. This paper aims to bridge this knowledge gap by investigating how distinct cytokine priming programs affect human NK cell responses to adenosine.

Methods

The researchers employed a multi-faceted approach to dissect the complex interactions between cytokine priming, adenosine, and NK cell function:

  • Primary Human NK Cell Isolation and Culture: NK cells were isolated from healthy adult donors and cultured under various conditions.
  • Cytokine Priming: NK cells were stimulated with different combinations of cytokines: IL-2, IL-15, and a combination of IL-12 and IL-15.
  • Adenosine Treatment: Cells were treated with adenosine (ADO) at a concentration mimicking tumor microenvironments.
  • Inhibitor Studies: Specific inhibitors were used to probe signaling pathways: an adenosine A2A receptor inhibitor (A2ARi) and an mTOR inhibitor (Torin-1).
  • Flow Cytometry: This was a core technique used to assess:
  • Expression of activation markers (e.g., NKG2D, NKp30).
  • Intracellular cytokine production (e.g., IFN-γ).
  • Phosphorylation of key signaling molecules (e.g., STAT5, S6).
  • Expression of CD73 on NK cells.
  • Cytotoxicity Assays: NK cell killing capacity against CD73+ cancer cell lines (A549) was measured using flow cytometry.
  • Seahorse Metabolic Assays: Mitochondrial respiration (Oxygen Consumption Rate - OCR) and glycolysis (Extracellular Acidification Rate - ECAR) were measured to assess metabolic activity.
  • RNA Sequencing (RNA-seq): Transcriptional profiles of NK cells under different conditions were analyzed to identify changes in gene expression.
  • Bioinformatic Analysis: This included differential gene expression analysis (DESeq2, edgeR) and Gene Set Enrichment Analysis (GSEA) to understand pathway-level changes.
  • Statistical Analysis: Standard statistical methods (t-tests, ANOVA, Kruskal-Wallis) were used to determine the significance of observed differences.

Datasets

Not discussed in the paper. The study primarily utilized primary human NK cells from healthy donors and established cancer cell lines (A549, K562) for in vitro experiments.

Key Insights and Ideas

  • Cytokine Priming Dictates Adenosine Sensitivity: The most striking finding is that NK cells are not uniformly suppressed by adenosine. Their response is highly dependent on the cytokine priming they receive. IL-12/IL-15 priming makes NK cells "hyper-responsive" to adenosine, leading to more pronounced effects compared to IL-2 priming.
  • mTOR is a Key Mediator: Adenosine's effects on NK cell function, particularly IFN-γ production, are significantly influenced by the mTOR pathway. Inhibiting mTOR with Torin-1 reversed some of adenosine's effects, highlighting its central role in adenosine-mediated signaling.
  • Metabolic Reprogramming: Adenosine doesn't just broadly inhibit NK cells; it specifically targets metabolic pathways. It downregulates genes involved in glycolysis and oxidative phosphorylation, suggesting a targeted metabolic suppression rather than a general shutdown.
  • IFN-γ Upregulation, Cytotoxicity Unchanged (Initially): While adenosine, in combination with IL-12/IL-15, significantly increased IFN-γ production, this didn't directly translate to increased killing of target cells. This suggests that other factors, possibly related to protein synthesis or granule exocytosis, might be limiting cytotoxicity despite enhanced cytokine production.
  • Adenosine Metabolism Matters: Inhibiting adenosine deaminase (ADA) with EHNA impacted NK cell cytotoxicity, suggesting that the balance of adenosine metabolism within the tumor microenvironment plays a critical role in modulating NK cell function.

Key Results

  • Enhanced IFN-γ Production: NK cells primed with IL-12 and IL-15 showed significantly increased IFN-γ expression in the presence of adenosine, especially the CD56<sup>bright</sup> subset. This effect was less pronounced with IL-2 priming.
  • Modulation of Activation Markers: Adenosine led to a decrease in NKG2D expression on IL-15-stimulated NK cells, but NKp30 expression remained largely unaffected.
  • Metabolic Inhibition: Adenosine significantly inhibited both oxidative phosphorylation and glycolysis in IL-12/IL-15-primed NK cells.
  • Transcriptional Changes: RNA-seq revealed that adenosine upregulates genes involved in immune signaling (including IFNG) and downregulates genes related to cellular metabolism and protein synthesis.
  • Cytotoxicity Paradox: While IFN-γ increased, direct NK cell-mediated killing of A549 cancer cells was not significantly reduced by adenosine under IL-2 or IL-12/IL-15 priming. However, inhibiting adenosine metabolism with EHNA did impact cytotoxicity.

Limitations and Future Work

  • Donor Variability: The study acknowledges significant donor variability in NK cell responses, which can complicate interpretation and requires careful statistical handling.
  • In Vitro vs. In Vivo: The findings are based on in vitro experiments, and their direct translation to the complex in vivo tumor microenvironment requires further validation.
  • Specific Adenosine Receptor Involvement: While the A2A receptor is implicated, the precise roles of other adenosine receptors (A1, A2B, A3) in these specific cytokine-primed responses warrant further investigation.
  • Therapeutic Implications: The authors suggest that understanding these cytokine-dependent responses to adenosine is crucial for designing more effective immunotherapies. Future work could focus on developing strategies to reprogram NK cell immunometabolism, potentially by combining cytokine therapy with adenosine pathway modulators, to enhance anti-tumor immunity in solid tumors. Investigating the impact of adenosine on NK cell subsets in different tumor types would also be valuable.

Summary updated

Abstract

Adenosine is a potent immunosuppressive purine metabolite contributing to the pathogenesis of solid tumors. Extracellular adenosine signals on tumor-infiltrating NK cells to inhibit their proliferation, maturation, and cytotoxic function. Cytokine priming imparts upon NK cells distinct activation statuses, which modulate NK anti-tumor immunity and responses to purinergic metabolism. Here, for the first time, we investigated human NK cell responses to adenosinergic signaling in the context of distinct cytokine priming programs. NK cells were shown to be hyper-responsive to adenosine when primed with IL-12 and IL-15 compared to IL-2, exhibiting enhanced IFN-γ expression from CD56<sup>bright</sup> and CD56<sup>dim</sup> subsets while modulating the expression of activation marker NKG2D. These responses resulted in signaling that was dependent on mTOR. Adenosine induced upregulation of transcriptional signatures for genes involved in immune responses while downregulating cellular metabolism and other protein synthesis functions that correlate to inhibited oxidative phosphorylation and glycolysis. Overall, our findings show that adenosine acts on specific cellular pathways rather than inducing a broad inhibition of NK cell functions. These responses are dependent on cytokine priming signatures and are important in designing therapeutic interventions that can reprogram NK cell immunometabolism for improved immunotherapies of solid tumors.
BibTeX
@inproceedings{chambers2018adenosinergic,
  author = {Andrea M. Chambers and Jiao Wang and Kyle B. Lupo and Hao Yu and Nadia A. Lanman and Sandro Matosevic},
  title = {{Adenosinergic Signaling Alters Natural Killer Cell Functional Responses}},
  booktitle = {Frontiers in Immunology},
  year = {2018},
  doi = {10.3389/fimmu.2018.02533},
}
Figure